A randomised, double-blinded trial to assess the effect of oclacitinib and prednisolone on intradermal allergen and prick tests in dogs with atopic dermatitis

Background: Intradermal (IDT) and prick (PT) tests are used to select allergens for allergen-specific immunotherapy in dogs with atopic dermatitis (cAD). However, the use of antipruritic drugs before performing these tests may influence the results.Objective: To evaluate the influence of the drugs oclacitinib and prednisolone on the immediate-phase reactions of IDT and PT.Animals: Thirty client-owned dogs with cAD with positive reactions to at least one allergen extract on IDT or PT.Materials and Methods: Dogs were randomly assigned to receive oclacitinib 0.4-0.58 mg/kg per os, every 12 h (n = 14), or prednisolone 0.37-0.65 mg/kg p.o., every 12 h (n = 16) for 14 days. IDT and PT were performed on Day (D)0 before treatment and on D14.Results: At D14 there was no significant reduction in the means of the orthogonal diameters of the positive immediate-phase reactions of the IDT (p = 0.064) in the oclacitinib group; however, in the PT, the diameter of the positive reactions reduced significantly (p = 0.048). In both tests, there was no significant reduction in the total number of positive reactions (IDT, p > 0.999; PT, p = 0.735). In the prednisolone group, the means of the orthogonal diameters of positive immediate-phase reactions were significantly reduced in both tests (IDT, p = 0.001; PT, p & LE; 0.001) and there also was a reduction in the total number of positive reactions (IDT, p = 0.022; PT, p = 0.001).Conclusions and Clinical Relevance: The use of oclacitinib 0.4-0.58 mg/kg twice daily for 14 days does not interfere with IDT results in dogs with cAD. However, oclacitinib may reduce PT reactivity. The use of prednisolone 0.37-0.65 mg/kg twice daily results in a reduction in both IDT and PT results.

Automated summary

This study evaluated the influence of the drugs oclacitinib and prednisolone on the immediate-phase reactions of intradermal (IDT) and prick (PT) tests. The results showed that oclacitinib may reduce PT reactivity, while prednisolone resulted in a reduction in both IDT and PT results.